2925-55-5 Usage
Uses
Used in Pharmaceutical Industry:
3-Fluoro-8-Quinolinesulfonyl Chloride is used as a clastogenic compound for its ability to induce chromosomal breakage and rearrangements in cells. This property makes it a valuable tool in the study of genetic mutations and the development of new therapeutic strategies for various diseases.
Used in Enzyme Inhibition:
3-Fluoro-8-Quinolinesulfonyl Chloride is used as an inhibitor of CYP enzymes, which are a family of enzymes involved in the metabolism of drugs and other substances in the body. By inhibiting these enzymes, the compound can potentially modulate the pharmacokinetics and pharmacodynamics of certain drugs, leading to improved efficacy and reduced side effects.
Used in Antibacterial Applications:
Due to the presence of the quinoline moiety, 3-Fluoro-8-Quinolinesulfonyl Chloride exhibits antibacterial properties. It can be used as an active ingredient in the development of new antibiotics or as a component in the synthesis of other antimicrobial agents, helping to combat bacterial infections and resistance.
Check Digit Verification of cas no
The CAS Registry Mumber 2925-55-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,9,2 and 5 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2925-55:
(6*2)+(5*9)+(4*2)+(3*5)+(2*5)+(1*5)=95
95 % 10 = 5
So 2925-55-5 is a valid CAS Registry Number.
2925-55-5Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 178; 179, (2014/09/29)
Compounds of general formula (I) and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Paragraph 0735; 0736, (2014/09/30)
Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 191; 192, (2014/09/29)
Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
